TY - JOUR
T1 - Standardising clinical outcomes measures for adult clinical trials in Fabry disease
T2 - A global Delphi consensus
AU - Moreno-Martinez, D.
AU - Aguiar, P.
AU - Auray-Blais, C.
AU - Beck, M.
AU - Bichet, D. G.
AU - Burlina, A.
AU - Cole, D.
AU - Elliott, P.
AU - Feldt-Rasmussen, U.
AU - Feriozzi, S.
AU - Fletcher, J.
AU - Giugliani, R.
AU - Jovanovic, A.
AU - Kampmann, C.
AU - Langeveld, M.
AU - Lidove, O.
AU - Linhart, A.
AU - Mauer, M.
AU - Moon, J. C.
AU - Muir, A.
AU - Nowak, A.
AU - Oliveira, J. P.
AU - Ortiz, A.
AU - Pintos-Morell, G.
AU - Politei, J.
AU - Rozenfeld, P.
AU - Schiffmann, R.
AU - Svarstad, E.
AU - Talbot, A. S.
AU - Thomas, M.
AU - Tøndel, C.
AU - Warnock, D.
AU - West, M. L.
AU - Hughes, D. A.
N1 - Publisher Copyright:
© 2021
PY - 2021/4
Y1 - 2021/4
N2 - Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD. Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi procedure. The aim was to reach a consensus regarding clinical trial design, best treatment comparator, clinical outcomes, measurement of those clinical outcomes and inclusion and exclusion criteria. Consensus results of this initiative included: the selection of the adaptative clinical trial as the ideal study design and agalsidase beta as ideal comparator treatment due to its longstanding use in FD. Renal and cardiac outcomes, such as glomerular filtration rate, proteinuria and left ventricular mass index, were prioritised, whereas neurological outcomes including cerebrovascular and white matter lesions were dismissed as a primary or secondary outcome measure. Besides, there was a consensus regarding the importance of patient-related outcomes such as general quality of life, pain, and gastrointestinal symptoms. Also, unity about lysoGb3 and Gb3 tissue deposits as useful surrogate markers of the disease was obtained. The group recognised that cardiac T1 mapping still has potential but requires further development before its widespread introduction in clinical trials. Finally, patients with end-stage renal disease or renal transplant should be excluded unless a particular group for them is created inside the clinical trial. Conclusion: This consensus will help to shape the future of clinical trials in FD. We note that the FDA has, coincidentally, recently published draft guidelines on clinical trials in FD and welcome this contribution.
AB - Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD. Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi procedure. The aim was to reach a consensus regarding clinical trial design, best treatment comparator, clinical outcomes, measurement of those clinical outcomes and inclusion and exclusion criteria. Consensus results of this initiative included: the selection of the adaptative clinical trial as the ideal study design and agalsidase beta as ideal comparator treatment due to its longstanding use in FD. Renal and cardiac outcomes, such as glomerular filtration rate, proteinuria and left ventricular mass index, were prioritised, whereas neurological outcomes including cerebrovascular and white matter lesions were dismissed as a primary or secondary outcome measure. Besides, there was a consensus regarding the importance of patient-related outcomes such as general quality of life, pain, and gastrointestinal symptoms. Also, unity about lysoGb3 and Gb3 tissue deposits as useful surrogate markers of the disease was obtained. The group recognised that cardiac T1 mapping still has potential but requires further development before its widespread introduction in clinical trials. Finally, patients with end-stage renal disease or renal transplant should be excluded unless a particular group for them is created inside the clinical trial. Conclusion: This consensus will help to shape the future of clinical trials in FD. We note that the FDA has, coincidentally, recently published draft guidelines on clinical trials in FD and welcome this contribution.
UR - http://www.scopus.com/inward/record.url?scp=85101623383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101623383&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2021.02.001
DO - 10.1016/j.ymgme.2021.02.001
M3 - Article
C2 - 33642210
AN - SCOPUS:85101623383
SN - 1096-7192
VL - 132
SP - 234
EP - 243
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
IS - 4
ER -
